Renal cell carcinoma treatment

Abstract

The present invention discloses a method of treating RCC patients who have not received or received treatment to obtain at least a partial tumor response, including administering a therapeutically effective amount of pegylated interferon alpha, such as pegylated alpha-2b, said interferon Use as a sole treatment or in combination with an effective amount of IL-2.

Description

Background of the invention [0001] The present invention relates to an improved therapy for the treatment of patients with renal cell carcinoma ("RCC"), wherein the treatment is achieved by administering a therapeutically effective amount of pegylated interferon-α within a time sufficient to obtain at least a partial tumor response. [0002] Metastatic renal cell carcinoma is usually resistant to chemotherapy with a single therapeutic agent or in combination. The use of immunotherapy, especially the use of interleukin-2 ("IL-2"), has been more successful. The use of high-dose intravenous IL-2 has achieved targeted tumor responses in approximately 14% of patients, some with long-term durability. Administration of high doses of IL-2 can cause capillary leak syndrome, resulting in hypotension and reduced organ perfusion. Such adverse effects can be serious and sometimes fatal. These toxicities generally limit the application of IL-2 to highly selected patients who are responsible for...

AI Technical Summary

Problems solved by technology

It must be noted that this response is slow and that 5 million IU interferon alfa-2b / m must be injected to achieve these results 2 , 3 times a week ("TIW")

In addition, interferon alfa-2b has many side effects that a large number of patients find unacceptable, and patient compliance with TIW injections of interferon alfa-2b has been problematic